Portal de Periódicos da CAPES

Cardio-renal benefits of sacubitril/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice

2022; BioMed Central; Volume: 23; Issue: 1 Linguagem: Inglês

10.1186/s12882-022-02919-z

1471-2369

María Dolores Martínez-Esteban, Teresa Vázquez-Sánchez, Rafael Pozo-Álvarez, Alicia Moreno-Ortiz, Juana Alonso-Titos, Guillermo Martín-Reyes, Pedro Ruiz‐Esteban, D. Gaitán Román, Domingo Hernández,

Cardiovascular Function and Risk Factors

Abstract Background The association between cardiac complications, such as heart failure (HF), and chronic kidney disease (CKD) is well known. In this study, we examined the effectiveness and safety of treatment with neprilysin inhibition in patients with advanced chronic kidney disease (stage 3b-4). Methods This single-centre, longitudinal, retrospective study of 31 months duration involved consecutive patients with CKD and HF with a reduced ejection fraction (HFrEF) who started treatment with sacubitril/valsartan. Glomerular filtration rate (GFR), cardiovascular risk factors, proteinuria, potassium, echocardiographic parameters and admissions for heart failure were analysed. Results The study comprised 25 patients with a median age of 73.2 ± 5.9 years. The most frequent aetiology of heart failure was ischemic heart disease. The median GFR was 29.4 ± 8.3 ml/min/1.73 m 2 and the left ventricular ejection fraction (LVEF) 36.4 ± 8.9%. The GFR improved after initiating the treatment (F = 3.396, p = 0.019), as did the LVEF at one year of follow-up ( p = 0.018). The number of visits to the emergency department for heart failure was also reduced. No patients needed to start renal replacement therapy. Conclusions This study shows that sacubitril/valsartan may play a beneficial role in patients who have advanced CKD and HFrEF, with a satisfactory safety profile.